Denali Therapeutics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Baillie Gifford & Co. has reported a beneficial ownership of 7.5% in Denali Therapeutics Inc. common stock as of June 30, 2026.
NASDAQ
T. Rowe Price Investment Management, Inc. has reported beneficial ownership of 16,178,963 shares, representing 10.2% of the outstanding common stock of Denali Therapeutics Inc.
NASDAQ
FMR LLC, through its subsidiaries, has reported a 4.2% beneficial ownership of Denali Therapeutics Inc. common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Denali Therapeutics Inc. following an internal realignment.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a 5.8% beneficial ownership stake in Denali Therapeutics Inc. common stock.
NASDAQ
Wellington Management Group LLP and its affiliates have reduced their beneficial ownership in Denali Therapeutics Inc. to 3.9% of common stock.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, reporting a continued 7.2% beneficial ownership stake in Denali Therapeutics Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Capital Research Global Investors Amends Stake in Denali Therapeutics, Holding 3.8% of Common Stock
Capital Research Global Investors has filed an amended Schedule 13G, disclosing a 3.8% beneficial ownership stake in Denali Therapeutics Inc. as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Baillie Gifford & Co Maintains Significant Stake in Denali Therapeutics, Discloses 8.56% Beneficial Ownership
Baillie Gifford & Co, a UK-based investment adviser, has filed an Amendment No. 7 to Schedule 13G, disclosing its continued beneficial ownership of 8.56% of Denali Therapeutics Inc.'s common stock as of December 31, 2024.